We use cookies to give you the best online experience. Please see our cookie policy here.

 Please let us know if you agree to all of these cookies..

Logo Logo
  • ABOUT
    • Overview
    • Leadership
    • Board
    • Scientific Advisors
    • F-star Partnerships
    • Careers
  • SCIENTIFIC APPROACH
    • Overview
    • Technology Platform
    • Publications
    • Intellectual Property
  • PIPELINE
    • Proprietary Pipeline
    • FS118
    • FS120
    • FS222
    • SB 11285
  • INVESTORS & NEWS
    • Overview
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • IR Resources
  • HOME
  • ABOUT
    • Overview
    • Leadership
    • Board
    • Scientific Advisors
    • F-star Partnerships
    • Careers
  • SCIENTIFIC APPROACH
    • Overview
    • Technology Platform
    • Publications
    • Intellectual Property
  • PIPELINE
    • Proprietary Pipeline
    • FS118
    • FS120
    • FS222
    • SB 11285
  • INVESTORS & NEWS
    • Overview
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • IR Resources
  • HOME
FStar

ABOUT

Home ABOUT
  • F-star Partnerships
    • Overview
    • Leadership
    • Board
    • Scientific Advisors
    • F-star Partnerships
    • Careers

    About

    F-star Partnerships

    The strength of F-star’s Modular Antibody Technology and mAb² programs have been leveraged through partnerships with leading biopharmaceutical companies within immuno-oncology and beyond.

     Pic About Investors Logo Merck

    2020: Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration

     

    2019: F-star expedites its transition to a wholly-owned portfolio strategy

     

    2017: F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology

     

    2011: Joint discovery and development of new antibody-derived therapeutic products

     DenaliVectorLogoGray

    2018: F-star Announces Early Exercise by Denali Therapeutics of its Option to Acquire F-star Gamma

     

    2016: F-star Announces Collaborative Agreement with Denali Therapeutics for the Development of a Multispecific Antibody Platform to Deliver Therapeutics Across the Blood-Brain Barrier

     
    • © 2020 F-star Therapeutics Inc.  By Emperor

    • Disclaimer
    • Privacy Policy
    • Cookie Policy
    • Careers
    • Contact Us
    • Sitemap
    • Get in touch